Introduction: This study includes 28 patients with genetically proven 22q11.2 deletion syndrome referred for treatment-resistant psychoses and aims at the identification of a suitable pharmacological treatment strategy. Methods: Based on standardized diagnostic procedures, key psychiatric symptoms and cognitive status were assessed. Also, data about previous diagnostic vignettes as well as the history of psychotropic medication and medical conditions were collected. Finally, the effect of the subsequent treatment regimen was periodically re-assessed. Results: Since psychotic symptoms had been shown to be non-responsive to conventional antipsychotics including risperidone, treatment with either clozapine or quetiapine was started. In 21 patients, a substantial reduction of psychotic symptoms was achieved with either one, and in 3-quarters of this group remission was attained over a longer follow-up period. In a significant number of patients, valproic acid was added either for mood stabilizing purposes or to avoid epileptic side effects of clozapine. Discussion: Treatment of psychotic symptoms in patients with 22q11DS with the atypical antipsychotic quetiapine or clozapine in combination with the mood-stabilizing anticonvulsant valproic acid, appears likely to be more effective than with other psychotropic compounds.

, , ,,
Pharmacopsychiatry: clinical pharmacology, psychiatry, psychology, neurophysiology, neurobiology, gerontopsychiatry
Department of Psychiatry

Verhoeven, W., & Egger, J. (2015). Atypical antipsychotics and relapsing psychoses in 22q112 deletion syndrome: A long-term evaluation of 28 patients. Pharmacopsychiatry: clinical pharmacology, psychiatry, psychology, neurophysiology, neurobiology, gerontopsychiatry, 48(3), 104–110. doi:10.1055/s-0034-1398612